18th WCIRDC Agenda

All Times in Pacific Time (Los Angeles, CA)
Thursday, December 3, 2020

8:00 am - 8:10 am

Welcome and Introduction

Yehuda Handelsman, MD, Chair

Session 1: Lipotoxicity: The Pathophysiologic Link Behind the Cardio-Metabolic Syndrome

Chairs: Ralph DeFronzo, MD • Robert Chilton, DO

8:10 am

8:30 am

9:10 am

8:50 am

9:30 am - 9:50 am

The Myocardium: Too Fat to be Fit

Fatty Kidney: The Renal Manifestation of the Metabolic Syndrome

Nonalcoholic Fatty Liver Disease and Diabetes: Clinical Implications of "Foie Gras"

The Beta Cell-Muscle Connection: A Fat Story   

Live Q&A Panel Discussion

Robert Chilton, DO

Ralph DeFronzo, MD

Kenneth Cusi, MD

Eric Ravussin, PhD

Session 2: Heart Disease in Women

Chairs: Tracey McLaughlin, MD • Matthew Budoff, MD

9:50 am

Sex Differences in Coronary Artery Calcium and Long-term CV Mortality     

10:10 am

Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women

10:30 am

10:50 am - 11:10 am

Estrogen Replacement Atherosclerosis and CVD

Live Q&A Panel Discussion

Martha Gulati, MD

Gina Lundberg, MD

Howard Hodis, MD

11:10 am - 11:55 am

Product Theater - Non CME 

An Approach to Managing Lipids: Oral Nonstatin Therapies for Lowering LDL-C

Supported By: ESPERION Therapeutics

Speaker TBD

Session 3: Lancet Diabetes & Endocrinology & 18WCRIDC Joint Session: COVID-19, DM Metabolism

Chair: Marta Koch, PhD

11:55 am

12:15 pm

12:35 pm

12:55 pm -1:15 pm

Two Pandemics in Collision: COVID-19 and Diabetes

Managing Patients with Diabetes and COVID-19

Obesity and Metabolic Surgery During and Beyond COVID-19

Live Q&A Panel Discussion

Paul Zimmet, AO, MD, PhD

Stefan Bornstein, MD

Geltrude Mingrone,MD

Session 4: CME Symposium: Heart Failure and Kidney Disease: The Next Epidemics 

Supported by AstraZeneca

1:15 pm

1:20 pm

1:40 pm

Introduction

Epidemiology and Traditional Management of HF and CKD

The Future Is Here: Contemporary Approach to HF with a Focus on HFrEF

Yehuda Handelsman, MD, Chair

Maria Rosa Costanzo, MD

Mikhail Kosiborod, MD

2:00 pm

2:20 pm

2:40 pm - 3:10 pm

Revolution in the Management of Moderate to Severe CKD           

Impact of Recent CVOTs on Contemporary Guidelines for HF and CKD

Panel Discussion and Q&A: The Cardiorenal Syndrome - Is it More Than the Sum of the Individual Components?

Katherine Tuttle, MD

Muthiah Vaduganathan, MD

Moderator: Peter McCullough, MD, PhD

Session 5: The Effects of Cancer and Cancer Therapy

Chairs: Derek LeRoith, MD, PhD • Zachary Bloomgarden, MD

3:10 pm

3:30 pm

3:50 pm

4:10 pm - 4:30 pm

Overview of the Interaction Between Obesity, Diabetes and Cancer Therapy

The Effect of Tyrosine Kinase, PI3K/mTor Inhibitors on Metabolism

Immunobiologics Effect on Diabetes: Type 1 and Type 2  

Live Q&A Panel Discussion

Derek LeRoith, MD, PhD

Emily Gallagher, MD, PhD

Kevan Herold, MD

4:30 pm - 5:30 pm Day 1 Summary
Friday, December 4, 2020

Session 6: Pediatric Obesity Management

Chairs: Sonia Caprio, MD • Alan Sinaiko, MD

8:00 am

8:20 am

Pharmacotherapy in the Management of Pediatric Obesity

Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults

8:40 am

Sleeve Gastrerctomy Impact on Cell Size and Genes from Adipose Tissue of Obese Adolescent Girls

9:00 am - 9:15 am

Live Q&A Panel Discussion

Aaron Kelly, PhD

Thomas Inge, MD, PhD

Sonia Caprio, MD

Session 7: What Should We Target to Treat Insulin Resistance? - Point-Counter-Point

Chairs: Richard Bergman, PhD • Bart Staels, PhD

9:15 am

9:35 am

The Ceramide Pathways as a Target for Insulin Sensitization

Diacylglycerols and acetyl-CoA as a Therapeutic Target for Insulin Resistance and Type 2 Diabetes

9:55 am -10:15 am

Audience Poll, Live Q&A Panel Discussion

Phil Scherer, PhD

Gerald Shulman, MD, PhD

Session 8: Lipids

Chairs: Paul Jellinger, MD • Ronald Krauss, MD

10:15 am

10:35 am

New Agents: PCSK9 siRNA (inclisiran) and Bempedoic Acid

Triglycerides and CVD: Causal or Coincidental? Lessons from Recent Research

10:55 am

The Role of LP(a) & ANGPTL3 in Lipids  Atherosclerosis and Cardiovascular Disease

11:15 am -11:35 am

Live Q&A Panel Discussion

Kausik Ray, MD

TBD

Norman Lepor, MD

11:35 am - 12:20 pm

Product Theater - Non CME 

Potential Mechanisms Responsible for the Effect of

Incretins on Atherosclerosis

Supported By: Lilly

Woody Corey, MD

Session 9: Insulin Focused Management of DM - Today and Tomorrow

Chairs: Vivian Fonseca, MD • Phil Scherer, PhD

12:20 pm

12:40 pm

Islet Cell Preservation & Replacement

Stem Cell Generated Human Islets Rescue Diabetes

Without a Device

1:00 pm

1:20 pm

1:40 pm - 2:00 pm

State of the Art Insulin Delivery Systems

Tomorrow’s New Insulin Today

Live Q&A Panel Discussion

Jay Skyler, MD

Ronald Evans, PhD

George Grunberger, MD

Julio Rosenstock, MD

Session 10: Metabolism & 18WCIRDC Joint Session: History of Insulin Resistance & Metabolism

Chair: Christos Mantzoros, MD, PhD

2:00 pm

2:05 pm

2:30 pm

2:55pm

3:20 pm - 3:40 pm

Introduction

Insulin Resistance and Cardiovascular Disease

Insulin Resistance, NAFLD/NASH and CVD Risk

Go with the Flow: Understanding Lipid Metabolism with Tracer Methods

Live Q&A Panel Discussion

Christos Mantzoros, MD, PhD

James Sowers, MD

Dimitri Mikhailidis, MD

Gerald Watts, PhD 

Session 11: Advanced Technologies & Genetics for Understanding & Managing IR & T2D

Chair: George Grunberger, MD

3:40 pm

4:00 pm

4:20 pm

4:40pm - 5:00 pm

Multiomics Analysis of IR vs IS Responses to Viral Infections, Exercise and Aging

Continuous Glucose Monitoring for Precision Diets

The Genetic Interrelationship Between T2D &

Coronary Heart Disease

Live Q&A Panel Discussion

Michael Snyder, PhD

Tracey McLaughlin, MD

Jerome Rotter, MD

5:00 pm - 6:00 pm Day 2 Summary
Saturday, December 5, 2020

Session 12: NAFLD/NASH

Chair: Sam Klein, MD

8:00 am

8:20 am

NASH- The Status of Diagnostics and Therapeutics

The Sexually Dimorphic Nature of NASH may Impact on Disease Progression and Responses to Drugs                

8:40 am - 8:55 am

Live Q&A Panel Discussion

Christos Mantzoros, MD, PhD

Bart Staels, PhD

Session 13: Atherosclerosis Cardiovascular Disease

Chair: Norman Lepor, MD

8:55 am

Anti-inflammatory Impact on Atherosclerosis and CVOT and Management Implications

9:15 am

Impact of Non Statin Drugs on Plaque Formation and Atherosclerosis

9:35 am

9:55 am -10:15 am

GLP1ra and Atherosclerosis- Human Data at Last

Live Q&A Panel Discussion

Jorge Plutzky, MD

Matthew Budoff, MD

Peter Reaven, MD

11:35 am - 12:20 pm

Product Theater - Non CME 

Supported By: Boehringer Ingelheim

Speaker TBD

Session 14: Obesity - Interventions

Chairs: Tim Garvey, MD • Sam Klein, MD

11:00 am

The Influence of Dietary Carbs, Fat, and Quality on

Ad Libitum Calorie Intake

11:20 am

Future of Obesity Pharmacotherapy: New Drugs and

New Targets 

11:40 am

12:20 pm

Effects of Bariatric Surgery on Cardiovascular Events

Does Intestinal Bypass Surgery Really Have Weight-Loss-Independent Therapeutic Metabolic Effects?

12:20 pm -12:40 pm

Live Q&A Panel Discussion

Kevin Hall, PhD

Tim Garvey, MD

Phil Schauer, MD

Sam Klein, MD

Speaker TBD

Product Theater - Non CME 

Supported By: Abbott

12:40 pm - 1:25 pm

Session 15: COVID-19 Pathophysiology and Advanced Management

Chairs: Richard Pratley, MD • Matthew Weir, MD

1:25 pm

1:45 pm

Obesity & COVID-19

Pathophysiological Basis & Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

2:05 pm

2:25 pm

2:45 pm - 3:05 pm

Convalescent Plasma in the Management of

COVID-19 Clinical Experience

Sex Differences in Mortality from COVID-19 Pandemic

Live Q&A Panel Discussion

Tracey McLaughlin, MD

Peter A. McCullough, MD

Ajay Nirula, MD, PhD

Erin D. Michos, MD

Session 16: CME Symposium: Emerging Standard of Care in the Prevention of Cardiovascular Morbidity and Mortality

Supported by Amarin

3:05 pm

3:10 pm

3:30 pm

Introduction

Primary and Secondary Prevention of CVD Current Standard of Care

High TGL Association with ASCVD Epidemiology and Pathophysiology

Yehuda Handelsman, MD, Chair

Deepak Bhatt , MD

Neha Pagidipati , MD

3:50 pm

4:10 pm

4:15 pm - 4:35 pm

IPE Impact on ASCVD Morbidity and Mortality

Lipid Guidelines IPE Related

Panel Discussion The New Standard of Care - Case based

Matthew Budoff , MD

Yehuda Handelsman , MD

Moderator: Deepak Bhatt , MD

4:35 pm - 5:35 pm Day 3 Summary
Sunday, December 6, 2020

Session 17: Cardiovascular Disease and Insulin Resistance

Chairs: Jorge Plutzky, MD • Robert Chilton, DO

8:00 am

8:20 am

8:40 am

9:00 am

9:20 am - 9:40 am

Insulin Resistance and Thrombotic Risk: Implications for Therapeutic Approaches to Vascular Disease

Update of Recent CV Outcome Trials

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with T2D: A Report of the American College of Cardiology

The Future of Cardiometabolic Care is Here: Announcing Cardiometabolic Center Alliance

Live Q&A Panel Discussion

Peter Grant, MD

Sanjay Kaul, MD

Brendan Everett, MD

Mikhail Kosiborod, MD

Session 18: Contemporary Aspects of Diabetes Management

Chairs: Peter Grant, MD • Jaime Davidson, MD

9:40 am

10:00 am

10:20 am

10:40 am -11:00 am

Managing Type 2 Diabetes to Prevent CVD-CKD: SGLT-2i,

GLP-1RA or Initial Combination of Both?

Hypoglycemia Impact and Management

The Role of CGM in Diabetes Update Toward 2021

Live Q&A Panel Discussion

Franceso Giorgino, MD, PhD

Vivian Fonseca, MD

Richard Bergenstal, MD

Speaker TBD

Product Theater - Non CME 

Supported By: Novartis

11:00 am - 11:45 am

Session 19: Obesity and CVD in Type 1 Diabetes

Chairs: Dan Einhorn, MD• Sonia Caprio, MD

11:45 am

The Current Management of CV Risk Factors in Type 1 Diabetes

Robert Eckel, MD

Debate: Should T2D Medications with proven CV benefits Be Used in T1D to Prevent ASCVD

12:05 pm

12:25 pm

Yes

Why Using T2D Medications with CVD Benefits is a Bad Idea for Type 1 Diabetes

12:45 pm - 1:05pm

Audience Poll, Live Q&A Panel Discussion

Richard Pratley, MD

David Nathan, MD   

Session 20: The Kidney in Diabetes

Chairs: Christian Mende, MD • Ralph DeFronzo, MD

1:05 pm

1:25 pm

KDIGO- Diabetes CKD and Hypertension New Guidelines 

GLP1-RA and SGLT2i in the Treatment of Diabetic Nephropathy: What Does the Future Hold?                 

1:45 pm - 2:00 pm

Live Q&A Panel Discussion

Matthew Weir, MD

David Cherney, MD

Speaker TBD

Product Theater - Non CME 

VASCEPA (icosapent ethyl): Elevating the Standard of Care

Supported By: Amarin

2:00 pm - 2:45 pm

2:45 pm - 3:45 pm

Abstract - Oral Presentation 

Zachary T. Bloomgarden, MD Chair   ●   Philip Levy, MD   ●   Daniel Einhorn, MD   ●   George Grunberger, MD

Session 22: Heart Failure and Management

Chair: Mikhail Kosiborod, MD

3:45 pm

4:05 pm

4:25 pm

4:45 pm - 5:05 pm

Lifestyle Modifications for Preventing and Treating Heart Failure

All We Need to Know about HFpeF     

Update on HFOT Impact on Management - Sequencing vs Initial Combination of Medication

Live Q&A Panel Discussion

Monica Aggarwal, MD

Carolyn Lam, MD 

Javed Butler, MD

5:05 pm - 6:00 pm Day 4 Summary

18372 Clark Street

Suite 212

Tarzana, CA 91356

info@tmioa.com

Phone: 818-342-1889
Fax: 818-342-1538

  • Facebook
  • Twitter

JOINTLY PROVIDED BY:

ADMINISTERED BY: